NextCure, Inc. (NXTC) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does NextCure, Inc. Do?
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. NextCure, Inc. (NXTC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael S. Richman and employs approximately 90 people. With a market capitalization of $37M, NXTC is one of the notable companies in the Healthcare sector.
NextCure, Inc. (NXTC) Stock Rating — Reduce (April 2026)
As of April 2026, NextCure, Inc. receives a Reduce rating with a composite score of 31.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NXTC ranks #3,263 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NextCure, Inc. ranks #494 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NXTC Stock Price and 52-Week Range
NextCure, Inc. (NXTC) currently trades at $11.64. The stock gained $0.43 (3.8%) in the most recent trading session. The 52-week high for NXTC is $15.74, which means the stock is currently trading -26.0% from its annual peak. The 52-week low is $0.22, putting the stock 5096.4% above its annual trough. Recent trading volume was 69K shares, suggesting relatively thin trading activity.
Is NXTC Overvalued or Undervalued? — Valuation Analysis
NextCure, Inc. (NXTC) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.13x, versus the sector average of 2.75x.
At current multiples, NextCure, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
NextCure, Inc. Profitability — ROE, Margins, and Quality Score
NextCure, Inc. (NXTC) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -165.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -115.5% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NXTC Debt, Balance Sheet, and Financial Health
NextCure, Inc. has a debt-to-equity ratio of 44.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $4M. Cash and equivalents stand at $7M.
NXTC has a beta of 0.77, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for NextCure, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
NextCure, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, NextCure, Inc. reported revenue of $0 and earnings per share (EPS) of $-19.65. Net income for the quarter was $-58M. Operating income came in at $-60M.
In FY 2025, NextCure, Inc. reported revenue of $0 and earnings per share (EPS) of $-19.65. Net income for the quarter was $-56M. Operating income came in at $-58M.
In Q3 2025, NextCure, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.22. Net income for the quarter was $-9M. Operating income came in at $-9M.
In Q2 2025, NextCure, Inc. reported revenue of $0 and earnings per share (EPS) of $-11.29. Net income for the quarter was $-27M. Operating income came in at $-27M.
Over the past 8 quarters, NextCure, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing NXTC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NXTC Dividend Yield and Income Analysis
NextCure, Inc. (NXTC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
NXTC Momentum and Technical Analysis Profile
NextCure, Inc. (NXTC) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 24/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
NXTC vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, NextCure, Inc. (NXTC) ranks #494 out of 838 stocks based on the Blank Capital composite score. This places NXTC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing NXTC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NXTC vs S&P 500 (SPY) comparison to assess how NextCure, Inc. stacks up against the broader market across all factor dimensions.
NXTC Next Earnings Date
No upcoming earnings date has been announced for NextCure, Inc. (NXTC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NXTC? — Investment Thesis Summary
The quantitative profile for NextCure, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Price momentum is positive at 68/100, suggesting the trend favors buyers. High volatility (stability score 26/100) increases portfolio risk.
In summary, NextCure, Inc. (NXTC) earns a Reduce rating with a composite score of 31.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NXTC stock.
Related Resources for NXTC Investors
Explore more research and tools: NXTC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NXTC head-to-head with peers: NXTC vs AZN, NXTC vs SLGL, NXTC vs VMD.